Citable company snapshot
ResMed's latest SEC-sourced 2026-03-31 period shows $1.43B in revenue and $398.73M in net income.
| Metric | Latest period | Latest value | Prior value | YoY |
|---|---|---|---|---|
| xbrl:RevenueFromContractWithCustomerExcludingAssessedTax | Mar 31, 2026 | $1.43B | $1.42B | +0.6% |
| xbrl:GrossProfit | Mar 31, 2026 | $890.98M | $878.72M | +1.4% |
| xbrl:OperatingIncomeLoss | Mar 31, 2026 | $499.81M | $491.66M | +1.7% |
| xbrl:NetIncomeLoss | Mar 31, 2026 | $398.73M | $392.59M | +1.6% |
| standalone via YTD differencing | Dec 31, 2025 | $339.75M | $457.32M | -25.7% |
| Free Cash Flow (computed) | Dec 31, 2025 | $311.21M | $414.36M | -24.9% |
Source: SEC EDGAR XBRL; period Mar 31, 2026; filed May 1, 2026; accession 0000943819-26-000025.
Continue research
Follow same-sector companies and source explainers connected to the overview view.
A factual guide to market capitalization, shares outstanding, public float, and why share-count definitions matter.
A factual guide to dividends, share repurchases, and how companies can return capital to shareholders.
A factual guide to book value, tangible book value, and balance-sheet net worth measures.
A factual guide to the core 10-K sections investors use for company context: business description, risk factors, MD&A, financial statements, and segment disclosures.